MEI Pharma Launches Historic $100M Litecoin Treasury Strategy in Landmark PIPE Deal

MEI Pharma, Inc. (NASDAQ: MEIP) has completed a groundbreaking $100 million private investment in public equity (PIPE), allocating all proceeds to acquire Litecoin (LTC) as its primary treasury reserve asset. Finalized on July 22, 2025, this move marks the first time a publicly traded U.S. company on a national exchange has adopted Litecoin as a core component of its balance sheet — pioneering a bold new corporate crypto treasury strategy.

The PIPE deal included the sale of 29.2 million shares priced at $3.42 per share, with Titan Partners Group serving as the sole placement agent. Investors in the round include prominent crypto-native firms such as the Litecoin Foundation, MOZAYYX, ParaFi, and others focused on digital asset innovation.

Charlie Lee Joins Board to Guide Digital Reserve Strategy

In a major leadership shift, Litecoin creator Charlie Lee has joined MEI Pharma’s board of directors, replacing Taheer Datoo, to help steer the company’s digital asset strategy.

“Litecoin was designed to be a faster, cheaper, and more efficient complement to Bitcoin, making it an ideal choice for companies seeking long-term stability and liquidity in digital assets,” said Lee.

To professionally manage its Litecoin holdings, MEI Pharma has engaged GSR, a leading global trading and investment firm specializing in digital assets.

Josh Riezman, Head of Sales at GSR, noted: “MEI Pharma’s adoption of Litecoin as a treasury reserve asset is a major step toward mainstream institutional acceptance of digital currencies.”

MEIP Stock Doubles as Market Rewards Bold Litecoin Treasury Pivot

Following the initial disclosure on July 18, MEI Pharma’s stock surged from $4.30 to an intraday high of approximately $8.40, marking a 95.35% spike on the news. The rally pushed shares back to levels not seen in over a year and a half, underscoring investor enthusiasm for the company’s bold and forward-looking crypto treasury strategy.

The company's investor relations page now includes updates and transparency reports related to the Litecoin acquisition, underlining MEI's intention to lead by example in the growing field of digital corporate finance.

As an open-source, proof-of-work cryptocurrency launched in 2011, Litecoin is known for its low transaction fees, faster block times, and high network reliability — making it well-suited for companies seeking stable and liquid crypto exposure. With over a decade of operational security and wide merchant acceptance, Litecoin presents a lower-risk entry point for public firms compared to more volatile, less-proven tokens.

Corporate Treasuries Are Moving Past the Crypto Blue Chips

MEI Pharma’s Litecoin adoption is part of a broader wave of crypto treasury innovation that’s rapidly expanding beyond Bitcoin. On July 21, crypto startup Ethena Labs — issuer of the algorithmic stablecoin USDe — was named as the target in a $360 million SPAC merger led by EXE Capital.

These developments reflect a growing institutional appetite for non-Bitcoin digital assets — from “digital silver” like Litecoin to programmable finance infrastructure like ENA — suggesting the next wave of treasury diversification is already underway.